Phreesia, Inc. (PHR)
Healthcare
- Fundamental
- 3
- Sentiment
- 2
- Technical
- 4
Buy limit 9.65 on a retest of the 9.60-9.70 breakout shelf; use 9.18 protective stop and take profits near 10.59 and 11.30, while treating it as a tactical long because the 200-day SMA is still overhead.
Company overview
Phreesia, Inc. provides a cloud-based SaaS and payment platform for the healthcare industry in the U.S. and Canada. Its platform streamlines patient intake and integrates payment processing through various modalities, including mobile applications and kiosks. The company serves diverse clients, including healthcare practices and life sciences firms.
Fundamental
fairPhreesia shows strong revenue growth and cash flow, but profitability and risk metrics remain weak.
Score 3/5 (Mixed): revenue growth has been strong (FY2026 $480.6M; 5-year revenue CAGR ~22.53%) and cash generation improved materially (FY2026 operating cash flow $78.8M). Valuation looks reasonable on EV/Sales (~1.45x) and attractive on free-cash-flow yield (~10.40%), but earnings are still thin (TTM net margin ~1.85% and P/E ~74x), and risk is elevated (interest coverage ~0.39x, Altman Z-score ~0.68, plus cybersecurity/legal risks highlighted in recent SEC filings).
Sentiment
weakSentiment is weak, dominated by legal overhangs and lack of near-term catalysts.
Last ~14d newsflow skews bearish and is dominated by plaintiff-law-firm class-action/deadline reminders (headline overhang, low-signal), while no actionable company-announced catalyst surfaced for the next 1–30 trading days. Baseline sentiment delta is indeterminate (baseline <3 in-window articles after date filtering) and the legal screen shows no regulator-confirmed investigation, leaving PHR in a weak, headline-driven setup.
Technical
goodShort-term momentum is positive with strong volume, but long-term trend remains unconfirmed.
PHR printed a high-volume bullish thrust on 2026-06-26, reclaiming SMA20, SMA50, EMA9, EMA21, WMA9, WMA21 and the daily VWAP in one session. RSI14 at 58.61 is constructive rather than exhausted, MACD has turned slightly positive versus a negative signal line, and ADX14 at 42.81 confirms a strong directional move. The main caveat is that price remains well below the 200-day SMA at 15.21, so this is a tactical short-term long rather than a fully repaired long-term trend.
You’re looking at 2026-06-28 — about 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.